-- 永明金融(Sun Life Financial,股票代码:SLF.TO)周四盘后宣布,已就一项涉及大都会人寿(MetLife)在上世纪八九十年代销售和签发的个人寿险保单的集体诉讼达成原则性和解。这些保单是永明金融通过收购继承的。 该公司表示,此事不涉及永明金融销售的任何保单或产品。 如果获得批准,永明金融将向符合条件的保单持有人支付高达2.135亿美元的和解金,预计将导致其2026年第一季度报告的净利润增加约1.45亿美元。 该诉讼涉及对保单条款的解释,这些保单受大都会人寿的赔偿保证约束。永明金融确认,如果和解获得批准,将根据赔偿保证向大都会人寿寻求全额赔偿。 此外,AM Best确认了Sun Life Financial旗下核心保险子公司——加拿大永明人寿保险公司(Sun Life Assurance Company of Canada)和美国永明人寿健康保险公司(Sun Life and Health Insurance Company (U.S.))的财务实力评级(FSR)为A+(优秀),长期发行人信用评级(Long-Term ICR)为“aa”(优秀)。AM Best同时确认了SLF的长期发行人信用评级(Long-Term ICR)为“a”(优秀),长期发行人信用评级(Long-Term IR)。这些评级的展望均为稳定。 这些评级反映了Sun Life集团强劲的资产负债表实力(AM Best评估为最强)、稳健的经营业绩、良好的业务状况以及非常强大的企业风险管理能力。 Sun Life Financial的股价在美国盘后交易中持平于72.08美元。该股在多伦多证券交易所收盘上涨1.30美元,报97.87美元。
Related Articles
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.
Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.
Briscoe Group Fiscal Q1 Sales Tick Higher
Briscoe Group (NZE:BGP, ASX:BGP) said its sales for the fiscal first quarter ended April 26 increased over 1% year over year to NZ$180.8 million, according to Friday filings with the Australian and New Zealand bourses.Sales in the company's homeware segment rose 2% to NZ$105.7 million, and sporting goods sales edged 0.5% higher to NZ$75.1 million.The company said discretionary consumer spending has dampened due to the Middle East conflict, with a noticeable impact on the retail sector during the latter part of the quarter, while bad weather in New Zealand also had a negative impact on store traffic.